Verve Therapeutics
VERV
VERV was delisted on the 24th of July, 2025.
73 hedge funds and large institutions have $1.81B invested in Verve Therapeutics in 2021 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 16 increasing their positions, 13 reducing their positions, and 30 closing their positions.
23% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 13
13% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 30
6% more funds holding
Funds holding: 69 → 73 (+4)
1.03% less ownership
Funds ownership: 81.71% → 80.68% (-1%)
19% less capital invested
Capital invested by funds: $2.25B → $1.81B (-$437M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$71.6M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$42.3M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$37M |
| 4 |
BlackRock
New York
|
+$24.4M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$14.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$41.3M |
| 2 |
Millennium Management
New York
|
-$24.7M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$18.5M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$14.9M |
| 5 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$11.4M |
VERV Hedge Fund Activity: Q3 2021 in Review
73 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Verve Therapeutics (VERV) for Q3 2021, worth a combined $1.81B — down 19% from $2.25B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new VERV positions and 30 closed out — a net gain of 4 holders — while 16 added to existing stakes and 13 trimmed.
The largest buyer was Vanguard Group, adding an estimated $71.6M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $41.3M sold.
- 73 institutional investors held Verve Therapeutics (VERV) as of Q3 2021, up from 69 in Q2 2021.
- Funds reported $1.81B of Verve Therapeutics stock for Q3 2021, down 19% quarter-over-quarter.
- 34 funds opened new Verve Therapeutics positions in Q3 2021 and 30 closed out, a net change of +4 holders.
- The largest Verve Therapeutics buyer in Q3 2021 was Vanguard Group, an estimated $71.6M added.
- The largest Verve Therapeutics seller in Q3 2021 was T. Rowe Price Associates, an estimated $41.3M sold.
Based on aggregated 13F filings for Q3 2021.